Proteases and metastasis

Clinical relevance nowadays?

Julie Decock, Robert Paridaens, Tanja Čufer

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose of review: A great deal of breast cancer research has been devoted to the search for new prognostic and predictive markers which could, on the one hand, enable a more precise identification of patients at high risk of recurrence and, on the other hand, predict the response of each individual patient to the administered therapy. Proteases have been the center of interest because of their prominent involvement in cancer progression and metastasis. In particular, the matrix metalloproteinases, the serine protease urokinase plasminogen activator, the cathepsins, and corresponding inhibitors have been studied extensively. This article reviews the developments during the last year in this field. Recent findings: The prognostic effect of urokinase plasminogen activator and plasminogen activator inhibitor 1 was confirmed in a meta-analysis and in a prospective randomized clinical study that provided level 1 evidence for the clinical value of these markers. Furthermore, encouraging data suggest that both urokinase plasminogen activator and plasminogen activator inhibitor 1 might be important predictive markers. To date, findings on the prognostic and predictive value of the matrix metalloproteinases, the cathepsins, and their inhibitors are still inconclusive. Summary: On the basis of currently available data, tumor urokinase plasminogen activator and plasminogen activator inhibitor 1 levels could already be used in everyday clinical practice for selection of candidates for adjuvant systemic therapy. Further effort should be put into the standardization of the matrix metalloproteinases and cathepsins determination so that their clinical relevance in breast cancer can be defined.

Original languageEnglish
Pages (from-to)545-550
Number of pages6
JournalCurrent Opinion in Oncology
Volume17
Issue number6
DOIs
Publication statusPublished - 1 Nov 2005
Externally publishedYes

Fingerprint

Plasminogen Activators
Urokinase-Type Plasminogen Activator
Cathepsins
Plasminogen Activator Inhibitor 1
Peptide Hydrolases
Matrix Metalloproteinases
Neoplasm Metastasis
Breast Neoplasms
Serine Proteases
Meta-Analysis
Neoplasms
Biomarkers
Recurrence
Therapeutics
Research

Keywords

  • Predictive value
  • Prognostic value
  • Proteases

ASJC Scopus subject areas

  • Cancer Research

Cite this

Proteases and metastasis : Clinical relevance nowadays? / Decock, Julie; Paridaens, Robert; Čufer, Tanja.

In: Current Opinion in Oncology, Vol. 17, No. 6, 01.11.2005, p. 545-550.

Research output: Contribution to journalArticle

Decock, Julie ; Paridaens, Robert ; Čufer, Tanja. / Proteases and metastasis : Clinical relevance nowadays?. In: Current Opinion in Oncology. 2005 ; Vol. 17, No. 6. pp. 545-550.
@article{2ad7b99582fa45038274931222099afb,
title = "Proteases and metastasis: Clinical relevance nowadays?",
abstract = "Purpose of review: A great deal of breast cancer research has been devoted to the search for new prognostic and predictive markers which could, on the one hand, enable a more precise identification of patients at high risk of recurrence and, on the other hand, predict the response of each individual patient to the administered therapy. Proteases have been the center of interest because of their prominent involvement in cancer progression and metastasis. In particular, the matrix metalloproteinases, the serine protease urokinase plasminogen activator, the cathepsins, and corresponding inhibitors have been studied extensively. This article reviews the developments during the last year in this field. Recent findings: The prognostic effect of urokinase plasminogen activator and plasminogen activator inhibitor 1 was confirmed in a meta-analysis and in a prospective randomized clinical study that provided level 1 evidence for the clinical value of these markers. Furthermore, encouraging data suggest that both urokinase plasminogen activator and plasminogen activator inhibitor 1 might be important predictive markers. To date, findings on the prognostic and predictive value of the matrix metalloproteinases, the cathepsins, and their inhibitors are still inconclusive. Summary: On the basis of currently available data, tumor urokinase plasminogen activator and plasminogen activator inhibitor 1 levels could already be used in everyday clinical practice for selection of candidates for adjuvant systemic therapy. Further effort should be put into the standardization of the matrix metalloproteinases and cathepsins determination so that their clinical relevance in breast cancer can be defined.",
keywords = "Predictive value, Prognostic value, Proteases",
author = "Julie Decock and Robert Paridaens and Tanja Čufer",
year = "2005",
month = "11",
day = "1",
doi = "10.1097/01.cco.0000180435.39614.63",
language = "English",
volume = "17",
pages = "545--550",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Proteases and metastasis

T2 - Clinical relevance nowadays?

AU - Decock, Julie

AU - Paridaens, Robert

AU - Čufer, Tanja

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Purpose of review: A great deal of breast cancer research has been devoted to the search for new prognostic and predictive markers which could, on the one hand, enable a more precise identification of patients at high risk of recurrence and, on the other hand, predict the response of each individual patient to the administered therapy. Proteases have been the center of interest because of their prominent involvement in cancer progression and metastasis. In particular, the matrix metalloproteinases, the serine protease urokinase plasminogen activator, the cathepsins, and corresponding inhibitors have been studied extensively. This article reviews the developments during the last year in this field. Recent findings: The prognostic effect of urokinase plasminogen activator and plasminogen activator inhibitor 1 was confirmed in a meta-analysis and in a prospective randomized clinical study that provided level 1 evidence for the clinical value of these markers. Furthermore, encouraging data suggest that both urokinase plasminogen activator and plasminogen activator inhibitor 1 might be important predictive markers. To date, findings on the prognostic and predictive value of the matrix metalloproteinases, the cathepsins, and their inhibitors are still inconclusive. Summary: On the basis of currently available data, tumor urokinase plasminogen activator and plasminogen activator inhibitor 1 levels could already be used in everyday clinical practice for selection of candidates for adjuvant systemic therapy. Further effort should be put into the standardization of the matrix metalloproteinases and cathepsins determination so that their clinical relevance in breast cancer can be defined.

AB - Purpose of review: A great deal of breast cancer research has been devoted to the search for new prognostic and predictive markers which could, on the one hand, enable a more precise identification of patients at high risk of recurrence and, on the other hand, predict the response of each individual patient to the administered therapy. Proteases have been the center of interest because of their prominent involvement in cancer progression and metastasis. In particular, the matrix metalloproteinases, the serine protease urokinase plasminogen activator, the cathepsins, and corresponding inhibitors have been studied extensively. This article reviews the developments during the last year in this field. Recent findings: The prognostic effect of urokinase plasminogen activator and plasminogen activator inhibitor 1 was confirmed in a meta-analysis and in a prospective randomized clinical study that provided level 1 evidence for the clinical value of these markers. Furthermore, encouraging data suggest that both urokinase plasminogen activator and plasminogen activator inhibitor 1 might be important predictive markers. To date, findings on the prognostic and predictive value of the matrix metalloproteinases, the cathepsins, and their inhibitors are still inconclusive. Summary: On the basis of currently available data, tumor urokinase plasminogen activator and plasminogen activator inhibitor 1 levels could already be used in everyday clinical practice for selection of candidates for adjuvant systemic therapy. Further effort should be put into the standardization of the matrix metalloproteinases and cathepsins determination so that their clinical relevance in breast cancer can be defined.

KW - Predictive value

KW - Prognostic value

KW - Proteases

UR - http://www.scopus.com/inward/record.url?scp=27644562231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644562231&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000180435.39614.63

DO - 10.1097/01.cco.0000180435.39614.63

M3 - Article

VL - 17

SP - 545

EP - 550

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -